Estrogen receptor degradation: A CUE for endocrine resistance?

Breast Cancer Research

Volumn 13, Issue 4, 2011, Pages

  Musgrove, Elizabeth A ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CUE DOMAIN CONTAINING PROTEIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; MEMBRANE PROTEIN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; CUEDC2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; DOWN REGULATION; HORMONE RESISTANCE; HUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; REGULATORY MECHANISM; BREAST TUMOR; DRUG RESISTANCE; ENDOCRINE SYSTEM; FEMALE; METABOLISM; PROTEIN TERTIARY STRUCTURE; REVIEW;

BREAST NEOPLASMS; CARRIER PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDOCRINE SYSTEM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MEMBRANE PROTEINS; PROTEIN STRUCTURE, TERTIARY;

EID: 84865152134     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2914     Document Type: Article

References (15)

1. Early Breast Cancer Triallists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717.
2. Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009, 9: 631-643. 10.1038/nrc2713.
3. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17: 1474-1481.
4. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thurlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007, 25: 3846-3852. 10.1200/JCO.2007.11.9453.
5. Pinzone JJ, Stevenson H, Strobl JS, Berg PE: Molecular and cellular determinants of estrogen receptor alpha expression. Mol Cell Biol. 2004, 24: 4605-4612. 10.1128/MCB.24.11.4605-4612.2004.
6. Madureira PA, Varshochi R, Constantinidou D, Francis RE, Coombes RC, Yao KM, Lam EW: The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem. 2006, 281: 25167-25176. 10.1074/jbc.M603906200.
7. Lonard DM, O'Malley BW: Emerging roles of the ubiquitin proteasome system in nuclear hormone receptor signaling. Prog Mol Biol Transl Sci. 2009, 87: 117-135.
8. Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH, Abdul-Karim FW, Montano MM, Keri RA: FOXA1 is an essential determinant of ERα expression and mammary ductal morphogenesis. Development. 2010, 137: 2045-2054. 10.1242/dev.043299.
9. Pan X, Zhou T, Tai YH, Wang C, Zhao J, Cao Y, Chen Y, Zhang PJ, Yu M, Zhen C, Mu R, Bai ZF, Li HY, Li AL, Liang B, Jian Z, Zhang WN, Man JH, Gao YF, Gong WL, Wei LX, Zhang XM: Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat Med. 2011, 17: 708-714. 10.1038/nm.2369.
10. Hicke L, Schubert HL, Hill CP: Ubiquitin-binding domains. Nat Rev Mol Cell Biol. 2005, 6: 610-621. 10.1038/nrm1701.
11. Zhang PJ, Zhao J, Li HY, Man JH, He K, Zhou T, Pan X, Li AL, Gong WL, Jin BF, Xia Q, Yu M, Shen BF, Zhang XM: CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J. 2007, 26: 1831-1842. 10.1038/sj.emboj.7601602.
12. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF: Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a geneexpression profiling study. Lancet Oncol. 2007, 8: 203-211. 10.1016/S1470-2045(07)70042-6.
13. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA: Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008, 26: 2473-2481. 10.1200/JCO.2007.13.6424.
14. Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD: LNCaP Atlas: gene expression associated with in vivo progression to castrationrecurrent prostate cancer. BMC Med Genomics. 2010, 3: 43-10.1186/1755-8794-3-43.
15. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis IO, Ali S, Lenz HJ, Stebbing J: Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med. 2011, 17: 715-719. 10.1038/nm.2351.